Taipei, Taiwan, July 10, 2025 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for June 2025 reached NT$1,044 million, a decrease of 6% decrease year-over-year (YoY) compared to same period last year. Lotus's June 2025 year-to-date (YTD) revenue stood at NT$9,477 million, representing an 6% YoY growth.
Lotus's Asia business saw an 11% YoY growth in revenue in June 2025 YTD. This was mainly attributable to the successful integration of Teva operations in Thailand and Alpha Choay in Vietnam, which drove revenue in Southeast Asia to grow at 176% for the same time period. Export markets were flat YoY compared to June 2024 YTD, where the double-digit YoY growth in Lenalidomide was partially offset by the decline in Subuxone.
In June, Lotus has signed an agreement to acquire a portfolio of five products in Vietnam. The closing to be expected to be in 3Q 2025 after the closing conditions are met. The portfolio covers a wide range of therapeutic areas, including hematology, CV, oncology and anti-inflammation. Sales of these products in Vietnam was around USD 8 million in 2024 and saw a compound annual growth rate (CAGR) of 22% in 2022-24, underscoring their strong commercial potential in the local market.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com